Bonetta Filler: A Professional Guide to Regulatory & Market Access

Bonetta is manufactured by ExoCoBio Inc., a company based in South Korea. The foundation of any injectable's quality assurance begins at the manufacturing level. For products originating from South Korea, key certifications to verify include KFDA (Korea Food and Drug Administration) approval and adherence to GMP (Good Manufacturing Practice) standards.

GMP certification ensures that products are consistently produced and controlled according to quality standards appropriate to their intended use. An ISO certification, such as ISO 13485 for medical devices, further demonstrates a manufacturer's commitment to a quality management system. When sourcing Bonetta, verifying these foundational certifications with your distributor is the first step in due diligence. These standards are often prerequisites for gaining market access in other regions.

For access to the EU market, a CE mark is mandatory for medical devices, including dermal fillers. The CE mark indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health, and environmental protection requirements. As of [VERIFY: Date], the specific CE certification status for the Bonetta filler line should be confirmed directly with your supplier.

For professionals in the UK, post-Brexit regulations require a UKCA (UK Conformity Assessed) mark, although CE-marked devices may be accepted for a transitional period. Clinics in these regions must ensure that any product they stock, such as Bonetta or alternatives from the hyaluronic acid dermal filler catalog, possesses the correct and valid conformity marking for their jurisdiction.

In the United States, dermal fillers are regulated by the Food and Drug Administration (FDA) as Class III medical devices. The FDA approval process is exceptionally rigorous and brand-specific. At present, Bonetta filler does not have FDA approval.

This means it cannot be legally marketed or sold for professional use within the US. Professionals based in the United States should not source or administer products that lack FDA approval. This is a critical point of compliance. For a comparative overview of regulatory pathways, see our Professional Guide: Onetox 100 Units Regulatory & Market Access.

Market access in the Gulf Cooperation Council (GCC), Latin America (LATAM), and Asia-Pacific (APAC) regions is governed by national or regional health authorities. Many of these authorities, such as the SFDA in Saudi Arabia, have their own registration requirements but may recognize certifications like a CE mark or evidence of GMP compliance as part of the registration dossier.

Bonetta's KFDA approval and GMP manufacturing background often facilitate its registration in these markets. However, its legal status can vary country by country. Distributors and resellers targeting these export markets must verify that Bonetta is registered with the local Ministry of Health before importing and distributing it. Sourcing a product like D.Fill Medium or Bonetta requires confirmation of local registration.

When sourcing any injectable, robust documentation is non-negotiable. It is your primary defense for compliance and patient safety. Regardless of the product, whether it is Bonetta, Elasty Plus 1CC, or another filler, your clinic must demand the following from your wholesale supplier:

Never accept products without complete and verifiable documentation. A reputable supplier will provide this information transparently. For related professional practices, refer to guides like the Professional Handling & Reconstitution Guide: Dysport 500 Un.